Related Experiment Videos
[Paroxysmal nocturnal hemoglobinuria, a cell surface molecular defect].
G K Hansson1, P S Seifert, I Högh-Kristiansen
1Medicinska kliniken II. Samtliga vid Sahlgrenska sjukhuset, Göteborg.
Lakartidningen
|October 3, 1990
Summary
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired anemia caused by defective protein attachment to blood cells. This defect, specifically the absence of decay-accelerating factor (DAF), leads to red blood cell destruction and hemolytic symptoms.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired blood disorder.
- It is characterized by hemolytic anemia, thrombosis, and bone marrow failure.
- PNH can progress to aplastic anemia or myeloid leukemia.
Observation:
- PNH is caused by a somatic mutation in the PIGA gene.
- This mutation leads to a deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins on hematopoietic cells.
- Key GPI-anchored proteins include decay-accelerating factor (DAF) and CD59.
Findings:
- The absence of DAF on blood cells impairs the complement regulatory system.
- This results in uncontrolled complement-mediated lysis of red blood cells, causing hemolysis.
- A case report illustrates the molecular defect in PNH.
Implications:
- Understanding the molecular basis of PNH is crucial for diagnosis and treatment.
- Targeting complement pathways offers therapeutic strategies for PNH.
- Further research into GPI-anchored protein deficiencies may reveal insights into other hematologic disorders.